Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

CoMentis

Overview

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Diabetic Macular Edema

Interventions

mecamylamineDRUG

topical ocular drops

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * macular edema due to diabetic retinopathy Exclusion Criteria: * vision loss from other ocular disease * intraocular surgery within 3 months * intraocular anti-VEGF or steroids within 3 months * HbA1c \>12

Locations (3)

East Bay Retina Consultants, Inc.

Oakland, California, United States

Johns Hopkins School of Medicine / Wilmer Eye Institute

Baltimore, Maryland, United States

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.